Real-world study of Benralizumab for severe asthma
Part of Blood & lymphatic, Immune system & allergy, Lungs & breathing clinical trials.
This study is for people with severe eosinophilic asthma who are about to start a medicine called Benralizumab (Fasenra). It will observe how the medicine works in real life, and requires you to answer some questions about your asthma every week and month.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with severe eosinophilic asthma (a type of asthma with high levels of certain white blood cells).
- You are using high-dose inhaled steroids plus a long-acting bronchodilator inhaler.
- Your doctor has already decided to start you on Benralizumab (Fasenra) before this study.
- You are willing to fill out short weekly and monthly asthma questionnaires.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new way to take asthma medicine using a device that tracks your inhaler use. If you already use Fasenra (benralizumab) for severe asthma, you may be able to join.
This study looks at people in China with severe eosinophilic asthma who are starting a new medicine called benralizumab. It will collect information about their symptoms and quality of life to understand who benefits most.
This study follows people with severe eosinophilic asthma who are starting benralizumab. It looks at how well the treatment works in real life, outside of a controlled research setting.
This study tests if adding a new injectable medicine (benralizumab) to your current medium-dose inhaler works better than simply increasing your inhaler dose to control hard-to-treat asthma. It may help people with a specific type of asthma linked to high eosinophil levels.
This study tests whether benralizumab, a biologic medicine, works well in real-world settings for people with severe asthma caused by an allergic reaction to a common mold called Aspergillus. You may qualify if you have hard-to-control asthma despite strong medications and recent asthma flare-ups.
This trial studies whether a specific “signature” from asthma tests can predict who will respond to benralizumab (a severe asthma biologic). If you qualify, the researchers will compare your test results to how well benralizumab controls your asthma and prevents flare-ups.
Hear when a new Asthma, Bronchial trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.